This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research Article
Engineering mesenchymal stem cells with neutralizing and anti- inflammation dual-capability against SARS-CoV-2 infection
Xuanming Yang
Sheng Yushou Center of Cell Biology and Immunology, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
The emergence of the novel human coronavirus SARS-CoV-2 has caused a worldwide epidemic of coronavirus disease 2019 (COVID-19), which markedly affected the global health and economy. Both uncontrolled viral replication and proinflammatory cytokine storm can cause severe tissue damage in COVID-19 patients. SARS-CoV-2 utilizes angiotensin-converting enzyme 2 (ACE2) as its entry receptor. In this study, we generated ACE2 extracellular domain-Fc and scFv-IL6R-Fc fusion protein to differentially neutralize virus and temper cytokine storm. The hACE21-740-Fc fusion protein showed potent inhibitory effect on pseudotyped SARS-CoV-2 entry and good safety profile in mice. The scFv-IL6R-Fc showed strong blockade effect on IL-6 signal activation. In addition, we established a mesenchymal stem cells (MSCs)-based hACE21-740-Fc and scFv-IL6R-Fc delivery strategy, which provided a potential rapid option for urgent clinic therapeutic need of COVID-19 patients.
Keywords
SARS-CoV-2, entry, mice, ACE2 extracellular domain-Fc and scFv-IL6R-Fc fusion protein
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
This is a list of supplementary files associated with this preprint. Click to download.
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 02 Jun, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Stem Cell & Developmental Cell Biology
Learn more about our company.
This is a preprint. It has not completed peer review.
Research Article
Engineering mesenchymal stem cells with neutralizing and anti- inflammation dual-capability against SARS-CoV-2 infection
Xuanming Yang
Sheng Yushou Center of Cell Biology and Immunology, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 02 Jun, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Stem Cell & Developmental Cell Biology
License:
This work is licensed under a CC BY 4.0 License. Read Full License
The emergence of the novel human coronavirus SARS-CoV-2 has caused a worldwide epidemic of coronavirus disease 2019 (COVID-19), which markedly affected the global health and economy. Both uncontrolled viral replication and proinflammatory cytokine storm can cause severe tissue damage in COVID-19 patients. SARS-CoV-2 utilizes angiotensin-converting enzyme 2 (ACE2) as its entry receptor. In this study, we generated ACE2 extracellular domain-Fc and scFv-IL6R-Fc fusion protein to differentially neutralize virus and temper cytokine storm. The hACE21-740-Fc fusion protein showed potent inhibitory effect on pseudotyped SARS-CoV-2 entry and good safety profile in mice. The scFv-IL6R-Fc showed strong blockade effect on IL-6 signal activation. In addition, we established a mesenchymal stem cells (MSCs)-based hACE21-740-Fc and scFv-IL6R-Fc delivery strategy, which provided a potential rapid option for urgent clinic therapeutic need of COVID-19 patients.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6